Lithium News and Research

RSS

Forest Laboratories, Pierre Fabre Laboratories announce that FETZIMA gets FDA approval for MDD

Forest Laboratories, Inc. and Pierre Fabre Laboratories announced today that FETZIMA (levomilnacipran extended-release capsules), a once-daily serotonin and norepinephrine reuptake inhibitor, discovered by Pierre Fabre Laboratories and co-developed by Forest Laboratories, Inc. was approved by the U.S. Food and Drug Administration for the treatment of Major Depressive Disorder in adults.

26 Jul 2013

Bodelin’s ProScope Micro Mobile picks up steam in dermatology

Bodelin Technologies' newly released ProScope Micro Mobile, the first professional-level microscope to be made specifically to attach to mobile devices such as the iPad, iPad mini, iPhone as well as other tablets and smartphones, has been picking up steam in the dermatology, Estheticians and hair restoration industries.

24 Jul 2013

Eisai submits BELVIQ NDS with Health Canada

Arena Pharmaceuticals, Inc. announced today that Eisai Limited (based in Mississauga, Ontario), a subsidiary of Eisai Inc., has submitted a New Drug Submission for BELVIQ (lorcaserin HCl) with Health Canada.

26 Jun 2013

Clinical psychologist to receive Rockefeller University's 2012 Lewis Thomas Prize for Writing about Science

Clinical psychologist and author Kay Redfield Jamison will be presented with Rockefeller University's 2012 Lewis Thomas Prize for Writing about Science at a ceremony on June 5, 2013. The award recognizes Jamison's 1993 book Touched with Fire: Manic-Depressive Illness and the Artistic Temperament, which examines the relationship between artistic creativity and mood disorders.

8 May 2013

Researchers discover new molecular mechanism to prevent edema formation

Researchers of the Max Delbr-ck Center for Molecular Medicine and the Leibniz Institute of Molecular Pharmacology in Berlin-Buch, Germany, have now detected a substance that can prevent the accumulation of fluid in body tissue and thus edema formation.

8 Apr 2013

New form of radiation cancer therapy with no harmful side-effects

Cancer painfully ends more than 500,000 lives in the United States each year, according to the Centers for Disease Control and Prevention. The scientific crusade against cancer recently achieved a victory under the leadership of University of Missouri Curators' Professor M. Frederick Hawthorne.

4 Apr 2013

Study explores a better alternative for treating bipolar disorder

Toxicity problems and adverse side effects when taking lithium, the mainstay medication for treating bipolar disorder, are fostering a scientific hunt for insights into exactly how lithium works in the body - with an eye to developing a safer alternative.

28 Mar 2013

AKAP protein alterations implicated in bipolar disorder

Researchers have found increased cellular expression of the postsynaptic signaling protein AKAP5/79 in the anterior cingulate cortex of patients with bipolar disorder.

8 Mar 2013

Brown University develops new implantable and rechargeable wireless brain sensor

A team of neuroengineers based at Brown University has developed a fully implantable and rechargeable wireless brain sensor capable of relaying real-time broadband signals from up to 100 neurons in freely moving subjects.

28 Feb 2013

Cortisol and white matter integrity relationship disrupted in bipolar disorder

Researchers have found evidence in support of hypercortisol-induced glial dysfunction affecting periventricular white matter integrity in patients with bipolar disorder.

14 Feb 2013

Four-step process delivers specific, reliable clinical rules

Dutch researchers have developed a four-step strategy for formulating clinical decision support systems, which they say could help reduce “alert fatigue.”

7 Feb 2013

Fifteen established scientists to receive NARSAD Distinguished Investigator Grants

The Brain & Behavior Research Foundation (formerly NARSAD, the National Alliance for Research on Schizophrenia and Depression) announced the latest recipients of its highly competitive NARSAD Distinguished Investigator Grants.

16 Jan 2013

Psychologic treatment has long-term benefits for bipolar patients

Psychoeducation and cognitive behavioral therapy combined with pharmacologic treatment provides significant long-term benefits for patients with refractory bipolar disorder, researchers report.

8 Jan 2013

Merck’s resubmission of the NDA for suggammadex sodium injection accepted for review by the FDA

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the resubmission of the New Drug Application (NDA) for sugammadex sodium injection has been accepted for review by the U.S. Food and Drug Administration (FDA). Merck expects the FDA’s review to be completed in the first half of 2013.

7 Jan 2013

Psychologic treatment has long-term benefits for bipolar patients

Psychoeducation and cognitive behavioral therapy combined with pharmacologic treatment provides significant long-term benefits for patients with refractory bipolar disorder, researchers report.

4 Jan 2013

New Spectra Iris indirect ophthalmoscope from Keeler

Spectra Iris is a new addition to Keeler's indirect ophthalmoscope range. It has been specifically designed as a compact, lightweight and portable indirect with an adjustable aperture for all pupil sizes.

20 Dec 2012

ADHD comorbidity confounds brain findings in bipolar disorder

Structural brain abnormalities found in patients with bipolar disorder may have been wrongly attributed to the condition and in fact be associated with comorbid attention–deficit hyperactivity disorder, US researchers believe.

7 Dec 2012

Researchers discover new cause of hydrocephalus

Researchers at the University of Iowa have discovered a new cause of hydrocephalus, a devastating neurological disorder that affects between one and three of every 1,000 babies born. Working in mice, the researchers identified a cell signaling defect, which disrupts immature brain cells involved in normal brain development.

20 Nov 2012

Brain's infralimbic cortex can switch between new and old habits

Habits are behaviors wired so deeply in our brains that we perform them automatically. This allows you to follow the same route to work every day without thinking about it, liberating your brain to ponder other things, such as what to make for dinner.

1 Nov 2012

FDA accepts Sunovion’s two LATUDA sNDAs for review

Sunovion Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review two supplemental New Drug Applications (sNDAs) for the use of LATUDA as 1) monotherapy and 2) adjunctive therapy to lithium or valproate, both to treat adult patients with depressive episodes associated with bipolar I disorder (bipolar depression).

31 Oct 2012